Your browser doesn't support javascript.
loading
Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial.
Yorgancioglu, Arzu; Öner Erkekol, Ferda; Mungan, Dilsad; Erdinç, Münevver; Gemicioglu, Bilun; Özseker, Zeynep Ferhan; Bayrak Degirmenci, Papatya; Nayci, Sibel; Çilli, Aykut; Erdenen, Füsun; Kirmaz, Cengiz; Ediger, Dane; Yalçin, Arzu Didem; Büyüköztürk, Suna; Öztürk, Sami; Güleç, Mustafa; Isik, Sacide Rana; Kalyoncu, Ali Fuat; Göksel, Özlem; Aydin, Ömür; Havlucu, Yavuz; Baloglu Ar, Idilhan; Erdogdu, Ahmet.
Afiliação
  • Yorgancioglu A; Department of Chest Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.
  • Öner Erkekol F; Department of Allergy and Immunology, Atatürk Chest Diseases and Thoracic Surgery Research and Training Hospital, Ankara, Turkey.
  • Mungan D; Division of Allergy and Immunology, Department of Chest Diseases, Faculty of Medicine, Ankara University, Ankara, Turkey.
  • Erdinç M; Department of Chest Diseases, Faculty of Medicine, Ege University, Izmir, Turkey.
  • Gemicioglu B; Department of Chest Diseases, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey.
  • Özseker ZF; Division of Allergy and Immunology, Department of Chest Diseases, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey.
  • Bayrak Degirmenci P; Department of Allergy and Immunology, Tepecik Research and Training Hospital, Izmir, Turkey.
  • Nayci S; Department of Chest Diseases, Faculty of Medicine, Mersin University, Mersin, Turkey.
  • Çilli A; Department of Chest Diseases, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
  • Erdenen F; Department of Internal Medicine, Istanbul Research and Training Hospital, Istanbul, Turkey.
  • Kirmaz C; Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.
  • Ediger D; Division of Allergy and Immunology, Department of Chest Diseases, Faculty of Medicine, Uludag University, Bursa, Turkey.
  • Yalçin AD; Department of Internal Medicine, Antalya Research and Training Hospital, Antalya, Turkey.
  • Büyüköztürk S; Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Öztürk S; Division of Allergy and Immunology, Department of Internal Medicine, Gulhane Military Medical Academy and Medical School (Haydarpasa), Istanbul, Turkey.
  • Güleç M; Division of Allergy and Immunology, Department of Internal Medicine, Gulhane Military Medical Academy and Medical School, Ankara, Turkey.
  • Isik SR; Department of Allergy and Immunology, Yedikule Chest Diseases and Thoracic Surgery Research and Training Hospital, Istanbul, Turkey.
  • Kalyoncu AF; Division of Allergy and Immunology, Department of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Göksel Ö; Division of Allergy and Immunology, Department of Chest Diseases, Faculty of Medicine, Ege University, Izmir, Turkey.
  • Aydin Ö; Division of Allergy and Immunology, Department of Chest Diseases, Faculty of Medicine, Ankara University, Ankara, Turkey.
  • Havlucu Y; Department of Chest Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.
  • Baloglu Ar I; Medical Department, Novartis Pharmaceuticals, Istanbul, Turkey.
  • Erdogdu A; Medical Department, Novartis Pharmaceuticals, Istanbul, Turkey.
Int Arch Allergy Immunol ; 176(3-4): 225-233, 2018.
Article em En | MEDLINE | ID: mdl-29772578
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos / Omalizumab Tipo de estudo: Observational_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Int Arch Allergy Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Turquia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos / Omalizumab Tipo de estudo: Observational_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Int Arch Allergy Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Turquia